Kevin Tang bought $13M of AUPH
Chief Executive Officer at Aurinia Pharmaceuticals Inc.. 900,000 shares at an average of $14.10, traded Feb 27, 2026, filed Mar 3, 2026.
Score components
- +15RoleDirector
- +25Trade size$12.7M at market
- +3Relative to holdingsHoldings up 8%
- 0Price contextNear the top of the 52-week range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +10.3%, 3m +8.8%, 6m +13.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001178579-26-000001, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 27, 2026 | POpen-market purchase Common Sharesindirect: By LP | +300,000 | $13.90 | $4.2M | 11,629,500 | Mar 3, 2026 |
| Feb 27, 2026 | POpen-market purchase Common Sharesindirect: By LP | +214,839 | $14.12 | $3.0M | 11,844,339 | Mar 3, 2026 |
| Feb 27, 2026 | POpen-market purchase Common Sharesindirect: By LP | +1,600 | $14.38 | $23k | 11,845,939 | Mar 3, 2026 |
| Mar 2, 2026 | POpen-market purchase Common Sharesindirect: By LP | +83,561 | $14.33 | $1.2M | 11,929,500 | Mar 3, 2026 |
| Mar 2, 2026 | POpen-market purchase Common Sharesindirect: By LP | +115,792 | $14.21 | $1.6M | 12,045,292 | Mar 3, 2026 |
| Mar 3, 2026 | POpen-market purchase Common Sharesindirect: By LP | +184,208 | $14.22 | $2.6M | 12,229,500 | Mar 3, 2026 |
Related signals
Other insiders at Aurinia Pharmaceuticals Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 27Weak | AUPHsell Aurinia Pharmaceuticals Inc. | Stephen P. Robertson Chief Legal Officer | $190k 11,939 shares | -2% | |
| 30Weak | AUPHsell Aurinia Pharmaceuticals Inc. | Stephen P. Robertson Chief Legal Officer | $356k 20,975 shares | -3% | |
| 53Moderate | AUPHbuy Aurinia Pharmaceuticals Inc. | Kevin Tang Chief Executive Officer | $12M 814,606 shares | +7% | |
| 43Moderate | AUPHbuy Aurinia Pharmaceuticals Inc. | Kevin Tang Chief Executive Officer | $14M 1,300,000 shares | +13% | |
| 32Weak | AUPHsell Aurinia Pharmaceuticals Inc. | Greg Keenan Chief Medical Officer | $210k 20,000 shares | -13% | |
| 38Weak | Aurinia Pharmaceuticals Inc. | Greg Keenan Chief Medical Officer | $68k 8,305 shares | -5% | |
| 48Moderate | AUPHbuy Aurinia Pharmaceuticals Inc. | Kevin Tang Chief Executive Officer | $13M 1,600,000 shares | +19% | |
| 65Notable | Aurinia Pharmaceuticals Inc. | Matthew Maxwell Donley Chief Operating Officer | $994k 124,893 shares | -16% | |
| 60Notable | Aurinia Pharmaceuticals Inc. | Stephen P. Robertson EVP, General Counsel | $975k 122,479 shares | -19% | |
| 66Notable | Aurinia Pharmaceuticals Inc. | Joseph M Miller Chief Financial Officer | $940k 118,013 shares | -17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.